Overview
- A peer‑reviewed modeling study published Oct. 19–20, 2026 estimates that delaying the first hepatitis B dose until two months would raise lifetime chronic infections by about 19% under a scenario with 75% uptake.
- The authors report a worst‑case shared‑decision scenario with only 26% uptake would produce a 225% increase in chronic infections, while an alternate model run with 50% uptake showed an 83% rise, illustrating that population uptake drives outcomes.
- The December 2025 CDC/HHS guidance that recommended shared clinical decision‑making for infants of mothers who test negative has been legally challenged by 15 states and temporarily blocked by a federal judge in March 2026, and professional groups including the AAP still endorse universal birth dosing.
- Researchers warn that even modest yearly increases in early‑life infections could accumulate into thousands more chronic cases, higher lifetime risk of cirrhosis and liver cancer for affected children, and increased health‑care spending.
- The dispute rests on tradeoffs between the decades‑old universal birth‑dose policy established in 1991, which prevents perinatal and household transmission, and the Kennedy administration’s view that infants of test‑negative mothers face lower risk, leaving policy, screening and implementation decisions unresolved as litigation proceeds.